Pipeline

OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED). OKYO plans to file the IND to treat DED in the fourth quarter of 2022, followed by the planned commencement of a Phase 2 trial in DED patients in the first quarter of 2023.